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Summary.-The lethal effect of high-dose melphalan in mice could be offset by
pretreatment with cyclophosphamide, cytosine arabinoside or low-dose melphalan.
The reason for improved survival is unclear. Although animals given high-dose
melphalan died with symptoms of gut death, in only one instance, that with low-dose
melphalan itself, did pretreatment protect the intestinal epithelium as measured by
the microcolony assay. A small enhancement in the recovery of the haemopoietic
tissue in pretreated animals was noted, although this on its own is unlikely to explain
the phenomenon. Experiments in tumour-bearing mice showed that pretreatment
with cyclophosphamide did not reduce the toxicity of melphalan to the Lewis lung
carcinoma.
SEVERAL biniary combinations of cyto-
toxic agents have been reported to have
less than the expected toxicity on normal
tissuesinmiceandrats. These combinations
generally take the form ofa small dose (the
pretreatment or priming dose) followed by
a large challenge dose of the same (Jeney
et al., 1968; Rose et al., 1975; Millar and
McElwain, 1978) or different cytotoxic
agent (Smith and Wilson, 1967; Jeney et
al., 1968; Schmidt et al., 1970: Millar et al.,
1975; Millar and Hudspith 1976; Millar et
al., 1978).
In this communication, the effect of
various pretreatments in reducing the
toxicity of a large dose of melphalan
(Melph) in mice is reported. The reaction
of the clonogenic cells in marrow and in-
testinal epithelium to a combination of
cyclophosphamide (Cyclo) and Melph is
investigated. Bearing in mind the im-
portance of normal-tissue-sparing combi-
nations in cancer chemotherapy, the
effectiveness ofthe sparing combination of
Cyclo and Melph on a murine tum-
our, the Lewis lung carcinoma is also
reported.
AIATERIALS AND AIETHODS
Aninmals.-8-10-week-old CBA or C57BL
male mice were used in survival studies, w'ith
never less than 10 animals per point. CBA
mice were used in normal-tissue toxicity
studies, whereas C57BL mice were used in
experiments involving the Lewis lung car-
cinoma. Mice ranged in weight between 22
and 27 g at the start.
Drugs.-All drugs w%Nere administered i.p.
Pure cyclophosphamide monohydrate (Cyclo)
(Endoxana, Koch-Light Ltd) was used. It was
dissolved in saline, as was cytosine arabino-
side. (AraC) (Cytosar, UpjohnLtd). Melphalan
(Melph) (Alkeran, Burroughs Wellcome & Co.)
was first dissolved in 1 ml of 2o% (v/v) acid
alcohol and then in saline to the required con-
centrations. All solutions were prepared
shortly before use.
Haemopoietic stem-cell assay.-Stem cells of
the femoral marrowv were assayed using the
technique of Till and McCulloch (1961). The
procedure for measuring peripheral-blood
leucocyte and granulocyte levels has been
reported elsewhere (Millar and Hudspith,
1976). There were 5 donor animals per group
and never less than 8 animals in recipient
groups or groups used to study peripheral
leucocyte recovery.J. L. MILLAR ET AL.
Studies on the intestinal epitheliumn.-Crypt
regeneration in the jejunum after Melph
treatment was assessed by a method similar
to the microcolony technique described by
Withers and Elkind (1970) after high doses
ofradiation. Mice were either treated with 20
mg/kg Melph alone, ortreated on various days
before with either 50 mg/kg Cyclo, 200 mg/kg
Ara Cor 5 mg/kgMelph, followed by20mg/kg
Melph. Four days after the high Melph injec-
tion, mice were given 20 IuCi 3H-TdR (Radio-
chemical Centre, Amersham) each and killed
40 min later. Three portions of each jejunum
were fixed in 10% formalin and then cut into
4-5 gam sections. Autoradiographywas carried
out to facilitate identification of viable re-
generating crypts. Sections were stained with
haematoxylin and eosin and counts made of
regenerating crypts/circumference and ex-
pressed as a proportion of the number of
crypts/circumference in untreated mice.
Lewis lung tumour.-Lewis lung tumours
were grown i.m. and treated in situ with
Melph. Some groups of mice received 50 mg/
kg Cyclo 2 days before the Melph. Either 18 h
or 72 h after the Melph treatment, single-cell
suspensions were made from the tumours, and
the number of surviving clonogenic cells was
assessed using the lung colony assay (Steel
and Adams, 1975). The lung colonies were de-
rived from surviving clonogenic tumour cells,
and the fraction of surviving clonogenic cells
per tumour was calculated, as has previously
been described (Stephens and Peacock, 1977).
RESULTS
Survival experiments
A dose of 20 mg/kg Melph killed 9/10,
8/10 and 7/10 animals in 3 separate experi-
ments. Thus, on average this dose ofMelph
killed 8/10 animals (Figs. la, b, c) 5-6 days
after treatment. Higher doses, 25 mg/kg,
30 mg/kg and 40 mg/kg proved fatal to all
the animals in 5 days or less. A dose of 50
mg/kg Cyclo was given at various times
before 20, 30 or 40 mg/kg Melph (Fig. la).
Improved survival was seen for at least
some intervals, at each dose level. At the
lowest dose ofMelph greatest survival was
seen when there was anintervalof2-3days
between pretreatment and challenge dose.
At the higher doses ofMelph, although few
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FiG. 1. Survival of animals given (a) 50 mg/
kg Cyclo at various times before 20 mg/kg
(0), 30 mg/kg (A) or 40mg/kg (M) Melph;
(b) 200 mg/kg Ara C at various times before
20 mg/kg (0), 30 mg/kg (A) or 40 mg/kg
(M) Melph; (c) 5mg/kg Melph at various
times before 20 mg/kg (0) or 25 mg/kg (*)
Melph. The effects of the various challenge
doses on their own are shown on the right
of each figure (±s.e.).
animals survived, an interval of 1 or 2 days
seemed more effective.
Ara C is effective as a pretreatment for
Melph (Fig. lb). A dose of 200 mg/kg Ara
C offset thelethal effect of20 mg/kgMelph,
and increased survival after 30 mg/kg
Melph, when the interval between the ad-
ministrations was 1 or 2 days. This pre-
treatment with Ara C did not improve
survival after 40 mg/kg Melph.
A pretreatment dose of 5 mg/kg Melph
2 or 3 days before 20 mg/kg Melph in-
creased the survival from 20% to 100%
(Fig. lc). When the challenge dose was
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FIG. 2.-Microcolonies in the gut 4 days after
20 mg/kg Melph, in animals pretreated with
50 mg/kg Cyclo (C) 200 mg/kg Ara C (A) or
5 mg/kg Melph (M). C3M indicates that
Cyclo was given 3 days before Melph, etc.
Mean± s.e.
increased to 25 mg/kg, 5 mg/kg Melph
treatment 2 days before the larger dose
improved survival.
Effect of melphalan on the intestinal
epithelium
The average number of regenerating
crypts per circumference of the jejunum
of mice 4 days after 20 mg/kg Melph is
shown in Fig. 2. All these colonies labelled
with 3H-TdR, suggesting that they were
viable colonies acting as foci for the re-
generation of the intestinal epithelium.
The crypt survival ofanimals given 50 mg/
kg Cyclo 3, 2 or 1 day before 20 mg/kg
Melph shows that animal survival (Fig. la)
may not have been related to crypt survi-
val with this treatment. Nor did the ad-
ministration of 200 mg/kg Ara C 2 days
before 20 mg/kg Melph improve crypt sur-
vival, though this treatment did not im-
prove animal survival either (Fig. lb).
With Melph pretreatment, there was a
DOSE OF MELPHALAN m-/!xg
FiG. 3.-Survival of marrow stem cells after
various doses of Melph. Normal animals
(*), animals given 50 mg/kg Cyclo 2 days
before (0). Mean±s.e.
correlation between crypt survival and
animal survival (Fig. lc).
Survival ofmarrowstemcellsaftermelphalan
The survival ofmarrow stem cells (CFU-
S) after various doses of Melph in normal
animals and in animals given 50 mg/kg
Cyclo 2 days before, is shown in Fig. 3.
There is no evidence that pretreatment
with Cyclo altered the sensitivity of the
stem cells to Melph. The small vertical
separation between the lines indicates the
effect ofthe 50 mg/kg Cyclo pretreatment.
Recoveryofmarrowstemcellsaftermelphalan
The recovery of bone marrow stem cells
after 15 mg/kg Melph was followed in
otherwise normal animals and in animals
given 50 mg/kg Cyclo 2 days before (Fig.
4). This dose of Melph allowed all control
animals to survive the duration of the
experiment. It can be seen that, although
the depression is slightlygreaterin animals
that received the pretreatment, recovery
took place at a greater rate. At Day 6, for
instance, the number of stem cells in pre-
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FiG. 4.-Recovery of marrow stem cells after
15 mg/kg Melph. Normal animals, solid
symbols; animals given 50 mg/kg Cyclo 2
days before the Melph, open symbols. Mean
±s.e.
treated animals was back to normal,
whereas in animals that received no pre-
treatment they were only 10% of normal.
Recovery ofperipheral-blood leucocytes after
melphalan
The peripheral-blood leucocyte level was
initially lower in animals given 50 mg/kg
Cyclo 2 days before 15 mg/kg Melph than
in animals that only received 15 mg/kg
Melph (Fig. 5). By Day 6, however, there
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FIG. 6.-Effect of various doses of Melph on
survival of clonogenic cells (SF=surviving
fraction) in tumours in normal animals
(solid symbols) or in animals treated with
50 mg/kg Cyclo 2 days before (open sym-
bols). The assay was performed 18 h (solid
lines) or 72 h (broken lines) after the mel-
phalan. Different shaped symbols refer to
separate experiments.
were 4times as manyperipheralleucocytes
in pretreated animals as in animals that
received Melph alone. Also, in pretreated
animals there was an overshoot between
Days 8 and 22 which was not seen in ani-
mals that received Melph alone. It is note-
worthy that the proportion of granulo-
cytes in the leucocyte count increased
steadily in both pretreated and control
animals during the course ofthe recovery.
Effect of melphalan on clonogenic Lewis
lung tumour cells
Fig. 6 shows that Lewis lung tumour
FIG. 5.-Recovery of peripheral leucocytes
(circles) and granulocytes (squares) in ani-
mals given 15 mg/kg Melph (solid symbols)
or 50 mg/kg Cyclo 2 days before 15 mg/kg
Melph (open symbols). Mean±s.e.
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cells were sensitive to Melph over the dose
range used for the normal tissue studies.
The sensitivity ofthese clonogenic tumour
cells was not altered if the animals were
treated with 50 mg/kg Cyclo 2 days before
the Melph. The small vertical displace-
ments between the lines shows the effect
of 50 mg/kg Cyclo on clonogenic tumour-
cell survival. The assay was performed at
18 h and at. 3 days after the Melph
challenge.
DISCUSSION
There are a nuimber of instances in
which it has been shown that pretreatment
with a cytotoxic agent increases the toler-
ance of an animal to a subsequent large
dose of the same or a different eytotoxic
agent.
In work with radiation, with challenge
doses up to 1000 rad when marrow is the
critical tissue, we have noted that the
response of marrow stem cells was the
same in normal and pretreated animals,
and that recovery, when it got under way
in each situation, proceeded at the same
rate (Millar et al., 1978). The difference was
in the time at which recovery began. In
pretreated animals there was little or no
post-irradiation lag, recovery beginning
promptly after irradiation (Smith et al.,
1968; Hanks and Ainsworth, 1967; Bre-
cher et al., 1967; Millar et al., 1978). This
suggests that the pretreatment dose pre-
pared the system for the challenge dose,
and recovery began promptly after the
challenge dose.
At higher doses of radiation the intes-
tinal epithelium becomes the critical tissue.
Pretreatment with Ara C 12 h before irra-
diation reduces the toxicity of the radia-
tion on this tissue (Boarder, 1976). In this
situation there appears to be a reduction
in the radiosensitivity of the tissue.
Pretreatment with a small dose ofCvclo
will offset lethality of an otherwise lethal
Cyclo dose (Millar and McElwain, 1978).
In this instance neither the marrow nor
the intestinal epithelium differed in their
response or recovery after Cyclo and the
cauise of death, and therefore the meehan-
ism by which pretreatment operated could
not be established. It was noted, however,
that the urothelium in pretreated animals
was in much better condition 24 h after a
large dose ofCyclo, ifthe animals had been
pretreated with the same drug.
In the present communication we have
demonstrated that pretreatment with Cy-
dlo will reduce the toxicity of Melph in
mice. Although animalstreatedwithMelph
alone appeared to die from gut failure
(death after about 5 days, with diarrhoea
and gross histological changes in the in-
testinal epithelium) it could not be estab-
lished that the sparing pretreatment with
Cyclo improved the condition of the in-
testinal epithelium, at least, using the
microcolony test available for study ofthis
tissue. The mechanism for improved sur-
vival, therefore, remains unclear. It was
established that Cyclo pretreatment did
not alter the sensitivity of marrow stem
cells to a subsequent challenge of graded
doses ofMelph up to and including 20 mg/
kg, yet there was a slightly earlier recovery
ofthese stem cells in animals given 15 mg/
kg Melph and the Cyclo pretreatment. It
is of interest that the peripheral leucocyte
count also recovered more rapidly in these
animals.
It is unlikely that the enhanced recovery
of the stem cells of the marrow could have
led tothe quickerrecovery intheperipheral
blood, because of the extremely short in-
terval between recovery of stem cells and
the onset ofperipheral leucocyte recovery.
Previous work (Millar et al., 1978) in which
enhanced survival of marrow improved
the survival of irradiated mice, has shown
that an interval ofabout 8 days is required.
for improved survival of stem cells to be
reflected in increased peripheral leucocyte
number.
Although the results of the survival
experiments could not be established with
great accuracy, as large numbers of ani-
mals were not used, it appeared from Fig.
1 that, as a rule, pretreatment 2 days be-
fore a challenge with high-dose Melph
provided the best survival, and this was
the case whether Cyclo, Aia C or low-dose
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Melph was used as the pretreatment. This
is consistent Nith the timing where radia-
tion was used as the challenge, and various
cytotoxic agents offset lethality (Millar et
al., 1978).
In conclusion, a similar type ofrecovery
to that studied in the marrow (Millar et al.,
1978) in pretreated animals cannot be
shown to operate in the gut by our present
methods. Other mechanisms, which might
involve interaction between gut and
marrow, must remain speculative. It is
noteworthy that Lewis lung tumour tissue
was not spared by Cyclo pretreatment, and
the potential therapeutic advantage of
pretreatment before large-dose challenge
should therefore be stressed. Pilot studies
in the clinic are in progress and have so
far yielded encouraging results.
The authors with to express their thanks to Dr
Gordon Steel for helpful discussion and advice and
to Miss Kay Adams for her expert technical assist-
ance.
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